Source comparison
Dosing Protocols: With DAC vs Without DAC
CJC-1295 exists in two forms with fundamentally different pharmacokinetic profiles, and the optimal dosing protocol depends entirely on which version is used. CJC-1295 with DAC (Drug Affinity Complex) contains a lysine-maleimide modification that allows the pe
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two forms with fundamentally different pharmacokinetic profiles, and the optimal dosing protocol depends entirely on which version is used. CJC-1295 with DAC (Drug Affinity Complex) contains a lysine-maleimide modification that allows the peptide to bind to serum albumin, extending its half-life to 6–8 days. This modification creates a sustained-release effect, maintaining elevated GH and IGF-1 levels throughout the week with a single injection. The standard research dose is 200mcg administered once every 7 days, typically in the evening to align with the body's natural nocturnal GH surge.
- CJC-1295 without DAC. Also called modified GRF 1-29 or Mod GRF. Lacks the albumin-binding modification and has a half-life of approximately 30 minutes, mirroring the pharmacokinetics of endogenous GHRH. This shorter half-life allows for more precise control over GH pulse timing but requires more frequent dosing to sustain effect. The typical protocol is 100mcg per injection, administered 2–3 times daily, with at least one dose before training and one dose before sleep to capitalise on exercise-induced GH amplification and nocturnal secretion windows.
- Here's what matters for fat loss outcomes: the DAC version produces steady-state IGF-1 elevation with less pronounced GH peaks, while the non-DAC version creates sharper, more physiological GH pulses that fade between doses. A 2017 comparative pharmacology study found that pulsatile GH protocols (mimicking non-DAC dosing) produced 30% greater lipolytic response than continuous GH elevation at equivalent cumulative exposure, suggesting that pulse amplitude. Not total GH area under the curve. Is the primary driver of fat oxidation. For researchers prioritising fat loss over convenience, non-DAC protocols at 100mcg 2–3 times daily outperform weekly DAC injections in most controlled applications.